1 / 9

An advocacy tool: Untangling the Web of Antiretroviral Price Reductions

An advocacy tool: Untangling the Web of Antiretroviral Price Reductions. Arax Bozadjian HIV Focused Pharmacist Access Campaign for Essential Medicines. History: Widely varying prices between on patent and off-patent medicines

indigo-shepard
Download Presentation

An advocacy tool: Untangling the Web of Antiretroviral Price Reductions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused Pharmacist Access Campaign for Essential Medicines

  2. History: Widely varying prices between on patent and off-patent medicines 1998 Thai NGO campaign for generic fluconazole sees price drop 97% in nine months Annual publication since 2000: provides ARV pricing in response to lack of transparent and reliable information Comprehensive pricing information provided by originator and generic manufacturers of ARVs Source of price comparison, patent information, access issues Used as advocacy tool; quoted in publications Available online: http://utw.msfaccess.org Untangling the Web: 15th edition

  3. Purpose and Methodology • Purpose: Help purchasers make informed decisions when purchasing ARVs for use in developing countries; used as an advocacy tool • How: Details originator and generic company prices of individual ARVs; analyzes price evolution • Methodology: • Questionnaire sent to companies (voluntary) • Information requested: ARV prices for developing countries; restrictions that apply to quoted prices • Generic manufacturers with at least one ARV WHO PQ are invited to participate • Limitation: • No commitment from manufacturer

  4. Practical use of UTW as a Tool • Increased Transparency of pricing and access policies • UTW provides both price and patent information • Market segmentation by innovator companies • Advantages of generic competition (first and second line ARVs) • Historical data

  5. The price of a third line regimen is 14 x more expensive than the most affordable first line regimen and over 6 x more than the most affordable second line regimen First, Second and Third Line ARV prices at present

  6. First Line Regimen:TDF/3TC/EFV

  7. Second Line Regimen: ATV/r

  8. Third Line Regimen: Darunavir

  9. Questions and/or comments? Thank You; Arax Bozadjian PharmD Arax.Bozadjian@geneva.msf.org

More Related